Meeting
2023 ASCO Annual Meeting
Impact of smoking status (SS) on the clinical outcomes of patients with metastatic renal cell carcinoma (mRCC) treated with first line (1L) immuno-oncology (IO)-combination regimens: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).
Authors
Georges Gebrael
Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT
Georges Gebrael , Eddy Saad , Chris Labaki , Renee Maria Saliby , Nicolas Sayegh , J Connor Wells , Karl Semaan , Marc Eid , Kosuke Takemura , Matthew Scott Ernst , Audreylie Lemelin , Naveen S. Basappa , Lori Wood , Thomas Powles , D. Scott Ernst , Anil Kapoor , Wanling Xie , Neeraj Agarwal , Daniel Yick Chin Heng , Toni K. Choueiri
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Kidney and Bladder
Track
Genitourinary Cancer—Kidney and Bladder
Sub Track
Kidney Cancer
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 4555)
DOI
10.1200/JCO.2023.41.16_suppl.4555
Abstract #
4555
Poster Bd #
47
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Real-world study of treatment patterns and clinical outcomes in patients with metastatic non-small cell lung cancer (mNSCLC) post-approval of immunotherapy in the community oncology setting.
First Author: Alexander I. Spira
Poster
2023 ASCO Genitourinary Cancers Symposium
Impact of number of treatment lines following first-line (1L) immuno-oncology (IO) combination on overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC).
First Author: Audreylie Lemelin
Poster
2020 ASCO-SITC Clinical Immuno-Oncology Symposium
A network meta-analysis of immunotherapy-based regimens for first-line treatment of advanced non-squamous non-small cell lung cancer.
First Author: Himani Agg
Poster
2023 ASCO Quality Care Symposium
Uptake and efficacy of immuno-oncology combinations in metastatic renal cell carcinoma in the United States: Evidence from the ASCO CancerLinQ Discovery database.
First Author: Joseph Vento